Finding Homes for Orphans

The unique challenges of researching, managing, and developing orphan drugs for rare diseases Rare diseases are having a moment, and not just in the field of hematology, where most of the “orphan diseases” find their...

Online Exclusives

No Settlements as Federal Opioid Cases Move to Trial

Judge Dan Aaron Polster of the Northern District of Ohio will preside over three consolidated federal lawsuits against makers and distributors of opioids in...

PhRMA Calls Out Foreign Countries Over Patent and Pricing Policies

PhRMA, the pharmaceutical industry’s trade group, filed comments with the Office of the U.S. Trade Representative asking for “urgent action” against two dozen countries...

News

From the Blood Journals

WIB_icon

Ibrutinib and Palbociclib: A New Combination for Mantle Cell Lymphoma?

The combination of ibrutinib and the CDK-4/6 inhibitor palbociclib could be safely administered to patients with previously treated mantle cell lymphoma (MCL), according to...
WIB_icon

A Pediatric Regimen Is Effective for Adolescents and Young Adults With...

Adolescents and young adults (AYAs) with newly diagnosed acute lymphocytic leukemia (ALL) who received a pediatric-inspired regimen had better survival outcomes than historical controls,...

Multimedia

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda

Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.

Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma

Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...

On Location

An ASH Annual Meeting Post-Vivum

“So, what did you learn from ASH?” asked my advisor a couple of weeks after...

Transplant or No Transplant for Older, Fit Patients With MDS?

Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with...

Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab...

Mixed Results for Immunotherapy Approaches in Myelodysplastic Syndromes

Findings from trials evaluating new treatment strategies for patients with myelodysplastic syndromes (MDS) produced mixed...

Predicting Response to Alvocidib in Patients With Relapsed/Refractory AML

The CDK9 inhibitor alvocidib induced a high rate of responses in patients with relapsed or...

Age, Blood Type, and Rituximab Use Associated With Relapse Risk in TTP

For patients with thrombotic thrombocytopenic purpura (TTP), treatment with rituximab prevented relapse in the first...

Latest Headlines

Advertisement

ASH Directions

An Advocacy Win for Sickle Cell Disease

An Advocacy Win for Sickle Cell Disease As part of a multifaceted initiative to address the burden of sickle cell disease (SCD) in the U.S....

ASH Recognizes Choosing Wisely Champions, Scholar Award Winners, and more

Recognizing Champions of Waste Reduction ASH recognized three Choosing Wisely® Champions during the 2018 annual meeting in San Diego. Choosing Wisely, an initiative of the American...

Sign up for our
eNewsletter!

Remembering Evan Sadler and Charles Dobbs, and more

Remembering Evan Sadler (1951 – 2018) Evan Sadler III, MD, PhD, the Lang Professor of Medicine and Chief of Hematology at Washington University in St....

Remembering Peter R. Galbraith and Sir David Weatherall, FDA names Amy Abernethy new Deputy...

Remembering Peter R. Galbraith (1931 – 2018) Peter R. Galbraith, MD, FRCPC, an emeritus professor at Queen’s University in Kingston, Ontario, passed away on October...

Remembering Brian P. Sorrentino, NIH Awards Washington University Leukemia Program, and more

Remembering Brian P. Sorrentino (1958-2018) Brian P. Sorrentino, MD, a gene-therapy researcher specializing in the treatment of blood and immune cell disorders, passed away...

Finding Homes for Orphans

The unique challenges of researching, managing, and developing orphan drugs for rare diseases Rare diseases are having a moment, and not just in the field...

New Drug Approvals in Nonmalignant Hematology

In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications...

Welcome to the Digital World

Over the past two decades, social media has become an integral part of everyday lives, with millions of people using it as an avenue...